Sphingosine 1-phosphate receptors and sphingosine kinase 1: novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers

Susan Pyne, Joanne Edwards, Jan OHOTSKI, Nigel J. Pyne

Research output: Contribution to journalArticlepeer-review

19 Downloads (Pure)


There is substantial evidence for a role in cancer of the bioactive lipid sphingosine 1-phosphate (S1P), the enzyme sphingosine kinase 1 (that catalyses S1P formation) and S1P-specific G protein-coupled receptors. This perspective highlights recent findings demonstrating that sphingosine kinase 1 and S1P receptors are new important biomarkers for detection of early cancer and progression to aggressive cancer. The impact of the sub-cellular distribution of S1P metabolizing enzymes and S1P receptors and their spatial functional interaction with oncogenes is considered with respect to prognostic outcome. These findings suggest that S1P, in addition to being a biomarker of clinical prognosis, might also be a new therapeutic target for intervention in cancer.
Original languageEnglish
Article number168
Number of pages5
JournalFrontiers in Oncology
Publication statusPublished - 3 Dec 2012


  • sphingosine 1-phosphate receptors
  • sphingosine kinase 1
  • novel biomarkers
  • hematological
  • clinical prognosis
  • breast
  • prostate
  • cancers
  • recurrence
  • sphingosine 1-phosphate
  • triple negative breast cancer
  • estrogen receptor
  • disease-specific survival

Cite this